Certolizumab Pegol: A New Therapeutic Approach for Acrodermatitis Continua of Hallopeau

Giulio Rizzetto; Federico Diotallevi; Elisa Molinelli; Giulia Radi; Anna Maria Offidani

doi:10.1159/000519144

Certolizumab Pegol: A New Therapeutic Approach for Acrodermatitis Continua of Hallopeau

Skin Appendage Disord. 2022 Mar;8(2):146-149. doi: 10.1159/000519144. Epub 2021 Sep 17.

Authors

Giulio Rizzetto¹, Federico Diotallevi¹, Elisa Molinelli¹, Giulia Radi¹, Anna Maria Offidani¹

Affiliation

¹ Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region, Ancona, Italy.

Abstract

Introduction: Acrodermatitis continua of Hallopeau (ACH) is a rare, chronic, and recurrent form of pustular psoriasis (PP) localized to one or more digits. Due to the rarity of ACH, no clear treatment guidelines are currently available, making the therapeutic approach more complex.

Case presentation: We report the first case of a young woman with ACH who was successfully treated with certolizumab pegol (CZP).

Discussion/conclusion: PP and ACH are difficult to treat, and biologics may be an option more manageable than cyclosporine. CZP is the safest biologic therapy during pregnancy, so there is low risk in prescribing it in women with childbearing potential. However, continuing biological therapy during pregnancy always involves an assessment of the clinical benefits, which must outweigh the risks.

Keywords: Acrodermatitis continua; Certolizumab pegol; Psoriasis.

Publication types

Case Reports